About Tirzepatide Peptide — An Independent Editorial Publisher

What this site is

Tirzepatide Peptide is an independent editorial project that publishes summaries of the peer-reviewed research literature on tirzepatide — the dual GIP/GLP-1 receptor agonist approved by the U.S. FDA for type 2 diabetes, chronic weight management, and obstructive sleep apnea.

We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The word 'peptide' in the site name is a descriptor — tirzepatide is a peptide, a 39-amino-acid synthetic molecule — not a claim about the site's services or medical scope. We are a reading room for the published record, not a prescriber, pharmacy, or clinical practice.

How we work

Every quantitative claim on this site is cited to a specific peer-reviewed publication, clinical-trial report, or regulatory document. Mechanism claims are grounded in the published receptor-pharmacology literature (Coskun et al. 2018, Willard et al. 2020, Novikoff et al. 2021, Sun et al. 2022, Douros et al. 2024). Clinical-outcome claims are grounded in the SURPASS and SURMOUNT phase 3 trial reports (NEJM, Lancet, JAMA) and systematic reviews. Safety claims are grounded in meta-analyses and FDA labelling.

We do not invent citations. We do not recommend doses or treatment decisions. We do not mention competitor brand names. We do not link to vendors, pharmacies, or clinical-service providers.

The human-layer material on the effects page — community-reported benefits and side effects — is clearly labelled as anecdotal, not clinical evidence, and is drawn from structured patient-interview research and pharmacovigilance data, not invented or extrapolated.

What we are not

This site is not a clinic, a telehealth provider, or a prescribing service. It does not advise on whether tirzepatide is appropriate for any individual. It does not offer consultations, prescriptions, or medical monitoring.

If you are considering tirzepatide or any prescription medicine, a licensed clinician is the appropriate resource — not an editorial website. The research summarised here is publicly available; the clinical judgment about its application to any individual belongs to a qualified healthcare professional.